Effects of purified fibronectin alone and combined with immunoglobulin G or antithrombin-III on survival during gram-negative peritonitis or endotoxemia in rats.
The present study was performed to determine the effects of pretreatment with purified human plasma fibronectin (FN) on survival in rats challenged with Salmonella typhimurium peritonitis or E. coli endotoxemia. The effects on survival of combining FN with immunoglobulin G (IgG) or antithrombin-III (AT-III) were also determined during S. typhimurium peritonitis and E. coli endotoxemia. Permanent survival was increased 15% in the peritonitis group (p less than 0.05) and 15% in the endotoxemic group (p greater than 0.05). There was no enhancement in survival by combining FN with a subprotective dose of IgG preparation. AT-III alone increased survival by 50% over survival in the control group. Combining FN with AT-III increased survival 10% greater than with AT-III alone, which is suggestive of an additive effect. Results from this study suggest that FN provides modest protection during Gram-negative peritonitis or endotoxemia in the rat. Combining FN with AT-III may augment in an additive manner the marked increase in survival observed with AT-III alone in this and previous studies.
Emerson
T E
TE
Department of Experimental Therapeutics, Cutter Biological, Miles Inc., Berkeley, CA 94710.
D000818:Animals; D000990:Antithrombin III / Q000627:therapeutic use*; D004927:Escherichia coli Infections / Q000628:therapy*; D005353:Fibronectins / Q000627:therapeutic use*; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D010538:Peritonitis / Q000209:etiology / Q000517:prevention & control*; D011292:Premedication; D051381:Rats; D011919:Rats, Inbred Strains; D012481:Salmonella Infections, Animal / Q000628:therapy*; D012486:Salmonella typhimurium; D012772:Shock, Septic / Q000209:etiology / Q000517:prevention & control*
D005353:Fibronectins; D007074:Immunoglobulin G; D000990:Antithrombin III